SHUKRAPHAR

SHUKRAPHAR · NSE

— · —

₹60.3

Closing price — 29 Sept 2026

Market cap ₹2,651 Cr · EPS ₹0.82

Valuation

Blended fair value using DCF and peer comparison methods.

See if SHUKRAPHAR is undervalued

Unlock intrinsic value for 4,800+ Indian stocks — free.

The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.

Peer comparison

How this company stacks up against sector peers on valuation and quality metrics.

Healthcare · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
SHUKRAPHAR SHUKRAPHAR · you	₹2,432 Cr	67.5×	45.0×	—	66.4%	0.6%	—
Sector median	—	45.1×	6.7×	25.1×	12.7%	6.8%	14.5%
Park Medi World Limited PARKHOSPS	₹12,549 Cr	40.9×	6.0×	27.2×	12.8%	15.4%	10.2%
Akums Drugs and Pharmaceuticals Limited AKUMS	₹12,161 Cr	45.1×	3.5×	20.9×	7.7%	5.9%	6.0%
Thyrocare Technologies Limited THYROCARE	₹9,929 Cr	60.9×	20.7×	—	34.0%	0.2%	—
Jupiter Life Line Hospitals Limited JLHL	₹9,880 Cr	53.4×	6.7×	29.1×	12.6%	12.9%	18.9%
Procter & Gamble Health Limited PGHL	₹9,850 Cr	27.6×	16.1×	—	58.5%	0.3%	—
Healthcare Global Enterprises Limited HCG	₹8,780 Cr	638.1×	6.6×	21.3×	1.0%	0.5%	14.5%
Sanofi India Limited SANOFI	₹7,249 Cr	45.1×	28.2×	23.0×	62.5%	27.3%	—
Nephrocare Health Services Limited NEPHROPLUS	₹6,944 Cr	83.4×	6.1×	28.8×	6.9%	7.7%	31.7%

Peer comparison verdict

SHUKRAPHAR trades at a premium to peers (P/E 73.5× vs median 45.1×), but its higher ROE of 66.4% (sector 12.7%) justifies much of that premium — quality rarely comes cheap.

Business quality

Valuation

P/E ratio

73.5×

P/B ratio

—

EV/EBITDA

—

Price/Sales

—

Returns

ROE

66.4%

ROCE

—

ROA

—

Growth

Revenue CAGR (3yr)

—

EPS CAGR (3yr)

—

Efficiency

Asset turnover

—

FCF yield

—

Dividend yield

—

Liquidity & Solvency

Debt / Equity

—

Debt / EBITDA

—

Interest coverage

—

Current ratio

—

Quick ratio

—

Financial health

Piotroski F-Score, Altman Z-Score, and key solvency ratios.

Financial health data is not yet available for this company.

Full financial data

Charts and annual statements for income, balance sheet and cash flow.

Income trend

Revenue, profit and margin trends over time.

Income statement data is unavailable for this company.

Cash flow

Where cash comes from and where it goes.

Cash flow data is not yet available for this company.

Balance sheet

Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.

Balance sheet data is not yet available for this company.

Numbers are illustrative — order-of-magnitude correct. For precise figures, refer to the company's annual report on BSE/NSE.

Shareholding pattern

Who owns this company and how that has changed.

Shareholding data is not yet available for this company.